Levosimendan use in several scenarios of acute heart failure
Arq Bras Cardiol. 2008 Mar;90(3):211-5.
doi: 10.1590/s0066-782x2008000300012.
[Article in
English,
Portuguese]
Affiliation
- 1 Department of Anesthesiology and Critical Care, Hospital Geral de Santo António, Porto - Portugal.
Abstract
In countries where it is available, early levosimendan infusion can be considered for patients who remain symptomatic with dyspnea at rest despite initial therapy, particularly those with a history of chronic heart failure or chronically treated with beta-blockers. Hypotensive patients or patients with active ischemia are not the best candidates for levosimendan administration and should have these problems addressed first.
MeSH terms
-
Acute Disease
-
Adrenergic beta-Antagonists / adverse effects
-
Cardiotonic Agents / administration & dosage
-
Cardiotonic Agents / therapeutic use*
-
Contraindications
-
Heart Failure / drug therapy*
-
Hemodynamics / drug effects
-
Humans
-
Hydrazones / administration & dosage
-
Hydrazones / therapeutic use*
-
Hypotension / complications
-
Ischemia / complications
-
Phosphodiesterase Inhibitors / adverse effects
-
Pyridazines / administration & dosage
-
Pyridazines / therapeutic use*
-
Simendan
-
Syndrome
-
Vasodilator Agents / administration & dosage
-
Vasodilator Agents / therapeutic use*
Substances
-
Adrenergic beta-Antagonists
-
Cardiotonic Agents
-
Hydrazones
-
Phosphodiesterase Inhibitors
-
Pyridazines
-
Vasodilator Agents
-
Simendan